Drug Repurposing Market Report 2026

The drug repurposing market size has grown strongly in recent years. It will grow from $37.38 billion in 2025 to $40.95 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to high cost and time of traditional drug discovery, increasing number of failed drug candidates, rising prevalence of chronic and rare diseases, limited therapeutic options for emerging diseases, early adoption of computational methods for drug repositioning.

The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $58.33 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to integration of ai and machine learning in drug repurposing, growing investment in biotech and pharma research, expansion of contract research organizations (cros) capabilities, rising demand for affordable therapies, regulatory support for repurposed drug approvals. Major trends in the forecast period include increasing focus on phenotypic and target-based screening, rising adoption of structure-based drug repositioning, growth in off-target activity identification approaches, expansion of drug repurposing for rare and infectious diseases, shortening drug development timelines through existing molecules.

The rising incidence of neurodegenerative diseases is anticipated to drive the expansion of the drug repurposing market in the coming years. Neurodegenerative diseases encompass a group of disorders marked by the progressive deterioration of neuron structure or function, ultimately leading to neuronal death. The increasing occurrence of neurodegenerative conditions, such as Alzheimer’s dementia, is largely attributed to longer life expectancy, as aging is the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing supports the management of neurodegenerative diseases by identifying existing medications with established safety profiles that can be redirected to target relevant disease pathways, thereby speeding up the development of effective therapies. For example, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections estimating this number will rise to 13.8 million by 2060. Consequently, the growing prevalence of neurodegenerative diseases is fueling the growth of the drug repurposing market.

Key companies operating in the drug repurposing market are emphasizing the development of advanced technologies, such as artificial intelligence (AI)-driven drug-protein interaction modeling, to accelerate the discovery of new therapeutic applications for existing drugs. AI-powered drug-protein interaction modeling utilizes artificial intelligence and machine learning techniques to predict how drugs interact with proteins across the human proteome, drawing on large-scale datasets to improve accuracy and reliability. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, launched Cloudscreen 2.0, an advanced AI platform designed for drug repurposing. This next-generation system is capable of processing datasets more than 100 times larger than earlier versions, enabling in-depth analysis of drug-protein interactions. By integrating mutagenesis data and tools for studying disordered proteins, the platform targets diseases including cancer, obesity, and diabetes. Furthermore, graphics processing unit (GPU)-based cloud computing enables scalable data processing, positioning the platform as a significant innovation in accelerating research and development pipelines for drug repurposing across diverse therapeutic areas.

In July 2025, Predictive Oncology Inc., a US-based artificial intelligence-driven drug discovery and repurposing company, entered into a partnership with YA II PN, Ltd., securing a $10 million share purchase agreement. Through this collaboration, Predictive Oncology seeks to further develop its AI-driven platform to speed up the identification of new therapeutic uses for existing drugs and to streamline oncology drug discovery workflows. YA II PN, Ltd. is a US-based investment fund managed by Yorkville Advisors Global, LP, a US-based investment management firm that provides financing to support such initiatives.

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug repurposing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the drug repurposing market by increasing costs for imported laboratory equipment, biologics, and research reagents, impacting segments such as biologics and small molecule repurposing. Regions like North America, Europe, and Asia-Pacific manufacturing hubs face increased import duties, leading to higher R&D expenses. However, tariffs have also encouraged local production of research tools, promoted domestic innovation, and improved investment in in-house repurposing capabilities, helping companies maintain long-term competitiveness.

The drug repurposing market research report is one of a series of new reports that provides drug repurposing market statistics, including drug repurposing industry global market size, regional shares, competitors with a drug repurposing market share, detailed drug repurposing market segments, market trends and opportunities, and any further data you may need to thrive in the drug repurposing industry. This drug repurposing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug repurposing involves discovering new therapeutic applications for existing or previously unsuccessful drugs. It utilizes established safety data and known pharmacological properties to shorten development timelines and lower costs. The objective is to accelerate the availability of treatments by avoiding the initial stages of drug discovery.

The primary forms of drug repurposing include disease-centric, target-centric, and drug-centric approaches. Disease-centric repurposing focuses on a particular disease and evaluates a range of existing drugs to determine their effectiveness in treating that condition, irrespective of their original biological targets. The drug molecules involved include biologics and small molecules. Therapeutic areas covered include oncology, neurology, infectious diseases, cardiovascular diseases, and autoimmune disorders, delivered through routes of administration such as oral, intravenous, topical, inhalation, and intramuscular, and serving end users including pharmaceutical companies, research and academic institutions, and contract research organizations.

The drug repurposing market consists of revenues earned by entities by providing services such as computational drug screening, clinical trial design and support, regulatory consulting, bioinformatics analysis, and data mining of existing drug databases. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug repurposing market also includes sales of thalidomide, sildenafil, minoxidil, metformin, and azithromycin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.